Abstract:Parkinson's disease (PD) is a common age-related neurodegenerative disorder characterized by the aggregation of α-Synuclein (αSYN) building up intraneuronal inclusions termed Lewy pathology. Mounting evidence suggests that neuron-released αSYN aggregates could be central to microglial activation, which in turn mounts and orchestrates neuroinflammatory processes potentially harmful to neurons. Therefore, understanding the mechanisms that drive microglial cell activation, polarization and function in PD might have important therapeutic implications. Here, using primary microglia, we investigated the inflammatory potential of pure αSYN fibrils derived from PD patients. We further explored and characterized microglial cell responses to a chronic-type inflammatory stimulation combining PD patient-derived αSYN fibrils (F PD ), Tumor necrosis factor-α (TNFα) and prostaglandin E 2 (PGE 2 ) (TPF PD ). We showed that F PD hold stronger inflammatory potency than pure αSYN fibrils generated de novo. When combined with TNFα and PGE 2 , F PD polarizes microglia toward a particular functional phenotype departing from F PD -treated cells and featuring lower inflammatory cytokine and higher glutamate release. Whereas metabolomic studies showed that TPF PD -exposed microglia were closely related to classically activated M1 proinflammatory cells, notably with similar tricarboxylic acid cycle disruption, transcriptomic analysis revealed that TPF PD -activated microglia assume a unique molecular signature highlighting upregulation of genes involved in glutathione and iron metabolisms. In particular, TPF PD -specific upregulation of Slc7a11 (which encodes the cystine-glutamate antiporter xCT) was consistent with the increased glutamate response and cytotoxic activity of these cells toward midbrain dopaminergic neurons in vitro. Together, these data further extend the structure–pathological relationship of αSYN fibrillar polymorphs to their innate immune properties and demonstrate that PD-derived αSYN fibrils, TNFα and PGE 2 act in concert to drive microglial cell activation toward a specific and highly neurotoxic chronic-type inflammatory phenotype characterized by robust glutamate release and iron retention.

Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation

A Self-Assembled α-Synuclein Nanoscavenger for Parkinson's Disease

Nanozyme scavenging ROS for prevention of pathologic α-synuclein transmission in Parkinson’s disease

Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson’s disease mouse model

Tryptophan-cardanol fluorescent nanoparticles inhibit α-synuclein aggregation and disrupt amyloid fibrils

Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis

Nanoparticles with Affinity for Α-Synuclein Sequester Α-Synuclein to Form Toxic Aggregates in Neurons with Endolysosomal Impairment

Lysosome-acidifying nanoparticles rescue A30P α-synuclein induced neuronal death in cellular and models of Parkinson’s disease

Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease

Recent advances of nanomaterials for intervention in Parkinson's disease in the context of anti-inflammation

Intranasal administration of -synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of <i>Macaca fascicularis</i>

Recent Advances of Nanomaterials for Intervention in Parkinson’s Disease in the Context of Anti-Inflammation

Neuroinflammation and Oxidation/Nitration of Alpha-Synuclein Linked to Dopaminergic Neurodegeneration

Brain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson's disease treatment via cooperative modulation of microglia

Parkinson's disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype

Nanotherapeutic Approaches of Interleukin-3 to Clear the α-Synuclein Pathology in Mouse Models of Parkinson's Disease

A Dual Synergetic Nanoreactor for Managing Parkinson's Disease by Regulating Inflammation and Mitigating Oxidative Damage

FoxO1 Alleviates the Mitochondrial ROS Levels Induced by α-Synuclein Preformed Fibrils in BV-2 Microglial Cells

Microglial LRRK2-mediated NFATc1 attenuates α-synuclein immunotoxicity in association with CX3CR1-induced migration and the lysosome-initiated degradation

α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity

Near-infrared Enhanced Organic Se-Doped Carbon Nitride Quantum Dots Nanozymes As SOD/CAT Mimics for Anti-Parkinson Via ROS-NF-κB-NLRP3 Inflammasome Axis